BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mayerhoefer ME, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S, Kornauth C, Senn D, Weber M, Wester H, Skrabs C, Haug A. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results. Invest Radiol 2018;53:403-8. [DOI: 10.1097/rli.0000000000000469] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Albano D, Dondi F, Bertagna F, Treglia G. The Role of [68Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. Cancers (Basel) 2022;14:3814. [PMID: 35954476 DOI: 10.3390/cancers14153814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Raderer M, Kiesewetter B, Mayerhoefer ME. Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment? Expert Rev Hematol 2022;:1-7. [PMID: 35695746 DOI: 10.1080/17474086.2022.2089110] [Reference Citation Analysis]
3 Di Rocco A, Petrucci L, Assanto GM, Martelli M, Pulsoni A. Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. Cancers (Basel) 2022;14:1742. [PMID: 35406516 DOI: 10.3390/cancers14071742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schottelius M, Herrmann K, Lapa C. In Vivo Targeting of CXCR4-New Horizons. Cancers (Basel) 2021;13:5920. [PMID: 34885030 DOI: 10.3390/cancers13235920] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
5 Dun Y, Huang G, Liu J, Wei W. ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality. Drug Discov Today 2021:S1359-6446(21)00500-6. [PMID: 34838729 DOI: 10.1016/j.drudis.2021.11.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Raderer M, Kiesewetter B. What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments. Ther Adv Med Oncol 2021;13:17588359211033825. [PMID: 34621332 DOI: 10.1177/17588359211033825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kuyumcu S, Kıran MY, Apaydın Arıkan E, Yeğen G, Şanlı Y. [68Ga]-Pentixafor PET/CT imaging of lymphoproliferative malignancies. Clin Transl Imaging 2021;9:641-8. [DOI: 10.1007/s40336-021-00458-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bergner C, Gummesson A, Joksch M, Sarvestani MK, von Helldorff H, Lapa C, Krause BJ, Schwarzenböck SM. Der Chemokinrezeptor CXCR4 – seine Entwicklung und Bedeutung in der nuklearmedizinischen Theranostik. Der Nuklearmediziner 2021;44:160-176. [DOI: 10.1055/a-1393-7958] [Reference Citation Analysis]
9 Albano D, Bertagna F, Dondi F, Annunziata S, Ceriani L, Giovanella L, Giubbini R, Treglia G. The Role of 2-[18F]-FDG PET/CT in Detecting Richter Transformation in Chronic Lymphocytic Leukemia: A Systematic Review. Radiation 2021;1:65-76. [DOI: 10.3390/radiation1010006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mayerhoefer ME, Raderer M, Lamm W, Pichler V, Pfaff S, Weber M, Kiesewetter B, Hacker M, Kazianka L, Staber PB, Wester HJ, Rohrbeck J, Simonitsch-Klupp I, Haug A. CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET. Theranostics 2021;11:567-78. [PMID: 33391493 DOI: 10.7150/thno.48620] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
11 Starzer AM, Berghoff AS, Traub-Weidinger T, Haug AR, Widhalm G, Hacker M, Rausch I, Preusser M, Mayerhoefer ME. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. Clin Nucl Med 2021;46:16-20. [PMID: 33208624 DOI: 10.1097/RLU.0000000000003404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
12 Zhao Z, Hu Y, Li J, Zhou Y, Zhang B, Deng S. Applications of PET in Diagnosis and Prognosis of Leukemia. Technol Cancer Res Treat 2020;19:1533033820956993. [PMID: 32875963 DOI: 10.1177/1533033820956993] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Pan Q, Luo Y, Zhang Y, Chang L, Li J, Cao X, Li J, Li F. Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG. EJNMMI Res 2020;10:89. [PMID: 32757068 DOI: 10.1186/s13550-020-00681-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
14 Osl T, Schmidt A, Schwaiger M, Schottelius M, Wester HJ. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Theranostics 2020;10:8264-80. [PMID: 32724470 DOI: 10.7150/thno.45537] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
15 Mayerhoefer ME, Haug A, Jäger U, Pichler V, Pfaff S, Wester HJ, Hacker M, Kazianka L, Staber PB. In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. Cancer Immunol Res 2020;8:984-9. [PMID: 32580942 DOI: 10.1158/2326-6066.CIR-19-0880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Mayerhöfer ME, Haug A. [Hybrid imaging in lymphoma]. Radiologe 2020;60:376-85. [PMID: 32296856 DOI: 10.1007/s00117-020-00676-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Spreckelmeyer S, Schulze O, Brenner W. Fully-automated production of [68Ga]Ga-PentixaFor on the module Modular Lab-PharmTracer. EJNMMI Radiopharm Chem 2020;5:8. [PMID: 32107654 DOI: 10.1186/s41181-020-0091-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Rangger C, Haubner R. Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology. Pharmaceuticals (Basel) 2020;13:E22. [PMID: 32019275 DOI: 10.3390/ph13020022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
19 Pan Q, Luo Y, Cao X, Li J, Li F. Posttreated POEMS Syndrome With Concurrent Follicular Lymphoma Revealed by 18F-FDG and 68Ga-Pentixafor PET/CT. Clin Nucl Med 2020;45:220-2. [PMID: 31977484 DOI: 10.1097/RLU.0000000000002923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 2019;134:1132-43. [PMID: 31292114 DOI: 10.1182/blood.2019000402] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 17.7] [Reference Citation Analysis]
21 Mayerhoefer ME, Archibald SJ, Messiou C, Staudenherz A, Berzaczy D, Schöder H. MRI and PET/MRI in hematologic malignancies. J Magn Reson Imaging 2020;51:1325-35. [PMID: 31260155 DOI: 10.1002/jmri.26848] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
22 Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, Keller U, Lapa C. CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med 2018;32:503-11. [PMID: 30105558 DOI: 10.1007/s12149-018-1290-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]